Efficacy of Pentoxifylline on Chronic Kidney Disease

National Taiwan University logo

National Taiwan University

Status and phase

Completed
Phase 4

Conditions

Chronic Kidney Disease

Treatments

Drug: pentoxifylline (drug)

Study type

Interventional

Funder types

Other

Identifiers

NCT00155246
930202

Details and patient eligibility

About

To study whether pentoxifylline has additive renoprotective effect in patients taking ARB

Full description

In patients with CKD and serum creatinine 1.3~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. Patients taking pentoxifylline or not will be compared for their spot urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups in a 2-year study. Add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months.

Enrollment

60 patients

Sex

All

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl

Exclusion criteria

  • History of allergy to pentoxifylline
  • Females are nursing or pregnant
  • Obstructive uropathy
  • Unable to stop chronic immunosuppressive therapy, NSAID
  • Congestive heart failure (New York Heart Association functional class III or IV)
  • Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form
  • Cerebral hemorrhage within the past 6 months prior to signing the informed consent form
  • Retinal hemorrhage within the past 6 months prior to signing the informed consent form
  • Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma)
  • Severe uncontrolled hypertension with SBP > 220 mmHg and/or DBP > 115 mmHg
  • Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 2 times the upper limit of the normal range
  • Biliary obstructive disorders (e.g. cholestasis)
  • Active malignancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems